Screening, intervention and outcome in autism and other developmental disorders: the role of randomized controlled trials.

Elisabeth and colleagues wrote a position paper. They asked: do we really need 20-year studies to prove early autism screening works?

The team reviewed ethical and practical roadblocks to super-long trials. They argue waiting decades wastes time kids don’t have.

The authors say rigorous short-term studies can show value. Good design, not long duration, is what counts.

They claim social importance, plus solid 1- to 3-year data, is enough to justify rolling out screening programs.

Lord et al. (2005) pushed the opposite view. That paper urged more RCTs and longer follow-ups before acting. The two reviews seem to clash, but they focus on different questions. Catherine looked at treatment proof; Elisabeth targets screening proof.

Real-world trials now follow Elisabeth’s playbook. Breider et al. (2024) ran a six-month parent-training RCT in clinics. Stewart et al. (2018) pooled 19 shorter parent-coaching studies and found small but real gains. Both show meaningful answers can come quickly.

Moore et al. (2003) adds backbone: autism diagnosed at age 2 stayed stable years later. Short-term screeners can therefore trust early labels, so lengthy re-checks aren’t required.

You can stop waiting for perfect decades-long data. Use brief, well-controlled studies to adopt or defend early screening in your region. Pair a validated tool like M-CHAT-R with a six-month outcome check—communication gains, parent stress, referral speed—to show funders results fast.